Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHL
- First Posted Date
- 2014-06-02
- Last Posted Date
- 2020-11-27
- Lead Sponsor
- Alopexx Oncology, LLC
- Target Recruit Count
- 5
- Registration Number
- NCT02151903
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL
- First Posted Date
- 2013-06-11
- Last Posted Date
- 2020-11-24
- Lead Sponsor
- Alopexx Oncology, LLC
- Target Recruit Count
- 24
- Registration Number
- NCT01874288
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸St. Jude Hospital Yorba Linda, Fullerton, California, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
News
No news found